ALung Technologies, now a part of LivaNova, is at the forefront of innovation in acute respiratory failure management. Their flagship product, the HEMOLUNG® System, is the world's first and only fully-integrated, FDA cleared system for extracorporeal CO2 removal (ECCO2R). This groundbreaking system effectively removes carbon dioxide directly from the blood at flow rates between 350 – 550 mL/min, offering a solution to mitigate the harmful effects of hypercapnia, respiratory acidosis, intubation, and ventilator-induced lung injuries.

The HEMOLUNG® System is a game-changer in the field, providing respiratory support for up to 5 days in adults with acute, reversible respiratory failure. It is designed for patients who cannot adequately or safely achieve CO2 ventilation through other available treatment options and who are expected to experience continued clinical deterioration. With its unique membrane surface area of 0.

59 m2 and heparin-coated polypropylene material, the system ensures optimal performance and safety. ALung Technologies is committed to delivering innovative solutions like the HEMOLUNG® System, revolutionizing respiratory support and improving patient outcomes. Learn more about their products, benefits, and ordering information on their website